0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02241174 |
Recruitment Status :
Withdrawn
(study materials have expired, no patients were enrolled)
First Posted : September 16, 2014
Last Update Posted : October 20, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atopic Dermatitis | Drug: Sodium Hypochlorite | Phase 1 |
Objective: To determine the safety and efficacy of 0.005% sodium hypochlorite final rinse solution on the reduction of Staphylococcus aureus colonization among children and adult Filipinos with mild to moderate atopic dermatitis.
Design: Randomized, double blind, controlled clinical trial. Setting: Makati Medical Center, Dermatology Outpatient Department Participants: Patients with mild to moderate atopic dermatitis, seen at Makati Medical Center Dermatology Outpatient Department.
Sample size: 68 (34 treatment group, 34 placebo group) Intervention: Eligible patients will be randomly allocated to two groups. The subjects will either be in the treatment group (0.005% sodium hypochlorite) or in the placebo group (bath water). Subjects will use a liter of 0.005% sodium hypochlorite as a final rinse solution during bathing for the treatment group and a liter of bath water for the placebo group. This intervention will be done twice a week for 12 weeks. Both patients and assessors will be blinded to the treatment assignments.
Assessment of Outcome: The outcomes will be assessed at weeks 4 and 12. Primary outcome measure will use culture findings, physician's global assessment (PGA) of severity of disease and eczema area and severity index (EASI) score. Secondary outcome measure will assess adverse effects during follow-up at weeks 4 and 12.
Data Analysis: Kruskal-Wallis Test will be used to compare the significant difference in scores between the two groups and Wilcoxon Signed Rank Test will be used to compare significant difference of before and after scores within each group.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of 0.005% Sodium Hypochlorite Final Rinse Solution on the Reduction of Staphylococcus Aureus Colonization in Atopic Dermatitis: A Randomized Controlled Trial |
Study Start Date : | July 2014 |
Estimated Primary Completion Date : | December 2014 |
Estimated Study Completion Date : | February 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Sodium Hypochlorite
The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
|
Drug: Sodium Hypochlorite
The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months |
Placebo Comparator: Placebo
100ml distilled water will be used as a placebo and will be stored on amber bottles identical with the treatment group
|
Drug: Sodium Hypochlorite
The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months |
- Culture and sensitivity findings [ Time Frame: 12 weeks ]The primary outcome of interest is the reduction of S. aureus colonization in skin lesion and the clinical improvement at week 4 and week 12.
- Eczema Assessment Severity Index (EASI) [ Time Frame: 12 weeks ]
Clinical decrease in the disease severity of atopic dermatitis Eczema Assessment Severity Index (EASI) b. Clinical decrease in the disease severity of atopic dermatitis Eczema Assessment Severity Index (EASI)
Body regions to be assessed:
- Head/Neck
- Upper extremities
- Trunk
- Lower extremities
In each of the body areas, the following key signs will be assessed:
- Erythema (E)
- Induration (I)
- Excoriation (Ex)
- Lichenification (L)
Scoring from the above features:
- 0 - none
- 1 - mild
- 2 - moderate
- 3 - severe
Body Surface Area involvement score:
- 0 = no eruption
- 1 = <10%
- 2 = 10%-29%
- 3 = 30% - 49%
- 4 = 50% - 69%
- 5 = 70% - 89%
- 6 = 90% - 100%
EASI Score Body region EASI Score Head/neck (E + I + Ex + L) x Area x 0.1 Upper extremities (E + I + Ex + L) x Area x 0.2 Trunk (E + I + Ex + L) x Area x 0.3 Lower extremities (E + I + Ex + L) x Area x 0.4 EASI Sum of above scores
- Physician Global Assessment (PGA) Scale [ Time Frame: 12 weeks ]
Severity of disease at baseline
Mild:
Moderate:
Severe:
Rating scale for PGA of Clinical Response at the end of the treatment
Rating % Improvement Week 4 Week 12
Cleared 100%
Excellent improvement 90-99%
Marked improvement 75-89%
Moderate improvement 50-74%
Slight improvement 30-49% No appreciable improvement 0-29%
- Adverse Effect [ Time Frame: 12 weeks ]An adverse effect is an adverse event for which the causal relation between the intervention and the event is at least a reasonable possibility. The term 'adverse effect' applies to all interventions, while 'adverse drug reaction' (ADR) is used only with drugs. Both will be measured in the study. All subjects will be asked if they have experienced any untoward effects from the intervention. In the event that any adverse events and adverse effects will be noted, immediate medical attention will be given to the participant(s) and the expenses of which, will be shouldered by the investigators.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 8 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Males and females more than 8 years old.
- Subjects with clinical diagnosis of atopic dermatitis (based on Hannifin and Rajka criteria).
- Healthy subjects with no other skin disease.
- Subjects without any prior topical or oral antibiotic two weeks prior to the enrollment period. Those who had undergone course of topical and oral antibiotic are given at least 2 weeks washout period.
Exclusion Criteria:
- Severe Atopic dermatitis requiring hospitalization.
- Hospitalized and debilitated patients.
- Subjects with other serious skin disorder, pigmentation or extensive scarring in affected areas.
- Subjects who have a known history or clinically relevant allergy, in particular to chlorine containing compounds.
- Pregnant women and nursing mothers.
- Subjects who are in a situation, which, in the opinion of the investigator, may interfere with optimal participation in the study.
- Subjects participating or having participated in a clinical trial within 1 month before enrollment in the study.
- Subjects who cannot communicate with the investigator (>18 years old) or are unaccompanied by parent or legal guardian (<18 years old).
- Subjects who are unable to follow-up.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02241174
Philippines | |
Makati Medical Center | |
Makati, NCR, Philippines, 1229 |
Principal Investigator: | Donna Marie L. Sarrosa, MD, FPDS | Makati Medical Center | |
Principal Investigator: | Jamaine Melisse L Cruz, MD | Makati Medical Center |
Responsible Party: | Jamaine Cruz, MD, Dr., Makati Medical Center |
ClinicalTrials.gov Identifier: | NCT02241174 |
Other Study ID Numbers: |
SodiumHypochloriteAD |
First Posted: | September 16, 2014 Key Record Dates |
Last Update Posted: | October 20, 2015 |
Last Verified: | October 2015 |
Atopic Dermatitis |
Dermatitis, Atopic Dermatitis Eczema Skin Diseases Skin Diseases, Genetic Genetic Diseases, Inborn Skin Diseases, Eczematous |
Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Sodium Hypochlorite Eusol Disinfectants Anti-Infective Agents |